Locations:
Search IconSearch

Cancer

23-CNR-4371811-CQD-Hero-650×450
January 4, 2024/Cancer/Innovations

Update on Phase 1 Trial of Preventive Breast Cancer Vaccine

Additional fine-tuning and recruiting of new patient groups underway

The Featured Image for the post
January 3, 2024/Cancer/Patient Support

Photo Essay: Support Services at Cleveland Clinic

Palliative and Supportive Care Teams offer comprehensive care to improve the lives of patients facing cancer

uterine transposition
January 3, 2024/Cancer

Innovative, Collaborative Care for Preserving Fertility

Options expand for patients with cancer and other conditions

23-CNR-4344312-CQD-Hero-650×450-Podcast
January 2, 2024/Cancer/Surgical Oncology

Exploring Focal Therapies for Prostate Cancer (Podcast)

Patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Dr. Shilpa Gupta
December 27, 2023/Cancer/Research

A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

adverse events from immune checkpoint inhibitors
December 21, 2023/Cancer/News & Insight

Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

23-NEU-4189360-hydrogen-sulfide-650×450

Can Boosting Hydrogen Sulfide Bolster Standard-of-Care Glioblastoma Therapy to Extend Survival?

Cleveland Clinic researchers pursue answers on basic science and clinical fronts

23-CNR-4318382-CQD-Hero-650×450 Dr Hill
December 19, 2023/Cancer/Research

Active Surveillance may be a Feasible Option for a Subset of Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Large cohort study finds no reduction in survival for patients managed with active surveillance compared to treated patients

Dr. Caimi
December 15, 2023/Cancer/Research

CAR-T Cell Therapy Effective in Refractory Double-Hit/Triple-Hit Lymphoma

Two thirds of patients responded to CAR T-cell therapy

BackPage 8 of 137Next

Advertisement

Ad